Why the study?
Do immature platelet fraction (IPF) and plasma thrombopoietin (TPO) predict mortality better than platelet count in patients suspected of having DIC?
Do immature platelet fraction (IPF) and plasma thrombopoietin (TPO) predict mortality better than platelet count in patients suspected of having DIC?
Immature platelet fraction and plasma thrombopoietin are potential new biomarkers for detecting DIC severity and predicting mortality better than standard platelet counts.
May aid mortality stratification in suspected DIC; hypothesis-generating and requires prospective validation before practice change.
Although platelet count is a good parameter for the diagnosis of disseminated intravascular coagulation (DIC), a single measurement of platelet is not enough to reflect the ongoing platelet consumption because of compensatory synthesis of circulating platelet number. Increased thrombopoiesis owing to peripheral destruction is expected in patients with DIC. Reticulated platelet, measured as immature platelet fraction (IPF), and plasma thrombopoietin (TPO) are markers of platelet production. We investigated the potential usefulness of circulating IPF and TPO in 222 patients suspected of having DIC. Both IPF and TPO levels were significantly increased in overt DIC patients and well correlated with DIC score. IPF also correlated with fibrin-related marker such as fibrinogen degradation product and D-dimer. Both IPF and TPO showed better mortality prediction than platelet count with the multivariate logistic regression and Kaplan-Meier survival analysis. These results suggest that IPF and TPO are new potential candidates to detect the severity of DIC and to predict DIC mortality.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: